Natco Pharma

Natco Pharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Natco Pharma (NATCOPHARM.NS) as of Oct 24, 2026 is 15.28 B INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 31.86 B INR — a change of -52.05% (lower).

EBITDA

15.28 BINR

YoY

-52.05%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Natco Pharma is 2026 15.28 B INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Natco Pharma was 2025 31.86 B INR. It decreases by -52.05% lower compared to the previous year.

The Natco Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
11.60 B INR
Jan 1, 2020
9.77 B INR
Jan 1, 2021
10.48 B INR
Jan 1, 2022
8.36 B INR
Jan 1, 2023
16.70 B INR
Jan 1, 2024
27.83 B INR
Jan 1, 2025
31.86 B INR
Jan 1, 2026
15.28 B INR
The Natco Pharma EBITDA history
YEAREBITDAYoY
15.28 BINR-52.05%
31.86 BINR+14.46%
27.83 BINR+66.66%
16.70 BINR+99.84%
8.36 BINR-20.27%
10.48 BINR+7.26%
9.77 BINR-15.73%
11.60 BINR-12.90%
13.31 BINR+21.63%
10.95 BINR+84.82%
5.92 BINR+36.85%
4.33 BINR+88.76%
2.29 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Natco Pharma Stock analysis

What does Natco Pharma do? Natco Pharma Ltd is an Indian pharmaceutical company that was founded in 1981. It is headquartered in Hyderabad, India and also operates branches in other parts of India and overseas. History Natco Pharma Ltd was founded by Dr. Devinder Pal Singh. The company started as a small generic drug manufacturing company but gradually expanded and today is one of the leading pharmaceutical companies in India. In the early 2000s, Natco Pharma Ltd entered the international market and has since conducted many important partnerships and acquisitions to expand its business. Business model Natco Pharma Ltd's business model focuses on the research, development, and manufacturing of drugs used in various therapeutic areas. The company primarily produces generics but also biosimilars and innovative products. Natco Pharma Ltd aims to provide affordable and accessible medications to patients in India and worldwide. Products and divisions Natco Pharma Ltd produces a wide range of medications divided into various divisions. The company's main divisions include oncology, hepatitis C, nephrology, neurology, cardiology, and anti-infectives. Natco Pharma Ltd also offers a range of biosimilars, including pegfilgrastim and trastuzumab, and has launched innovative products such as Natdac (daclatasvir) and Hepcinat LP (sofosbuvir and ledipasvir). The company also has a separate department for the production of active pharmaceutical ingredients (APIs) and has multiple manufacturing facilities in different parts of India certified by strict international quality standards (such as USFDA, UK-MHRA, and TGA). Activities Natco Pharma Ltd has been involved in several patent litigation cases to facilitate access to affordable generic medications. A significant example is the patented cancer drug Nexavar by Bayer. Natco Pharma Ltd won a long legal battle, allowing it to bring a cheaper version of the drug to the market. Natco Pharma Ltd has also built partnerships with other pharmaceutical companies to promote the distribution of its medications on a global level. One important collaboration of the company is with Mylan to manufacture affordable versions of HIV/AIDS medications for developing countries. Conclusion Natco Pharma Ltd is a strong example of a company that has been able to grow through quality, research, and affordable products. It has also been involved in several patent disputes to improve access to affordable medications. The wide range of medications and divisions shows that Natco Pharma Ltd is a significant player in the Indian and international market. Natco Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Natco Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Natco Pharma is 15.28 B INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Natco Pharma changed from 31.86 B INR to 15.28 B INR, representing a -52.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Natco Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Natco Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Natco Pharma

All Key Metrics — Natco Pharma